Tositumomab and iodine I 131 tositumomab (Bexaar)

American Journal of Neuroradiology

Volumn 32, Issue 4, 2011, Pages 637-638

  Srinivasan, Ashok ^a   Mukherji, S K ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEXAAR; RITUXIMAB; TOSITUMOMAB I 131; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANGIONEUROTIC EDEMA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLEEDING; BRONCHOSPASM; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; COMPLEMENT DEPENDENT CYTOTOXICITY; CYTOPENIA; DEHYDRATION; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG SAFETY; HUMAN; LEUKEMIA; MEDICARE; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PLEURA EFFUSION; PNEUMONIA; RADIATION DOSE; RADIOIMMUNOTHERAPY; SEPSIS; SURVIVAL TIME; THROMBOCYTOPENIA;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; LYMPHOMA, NON-HODGKIN; RADIOIMMUNOTHERAPY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79954465051     PISSN: 01956108     EISSN: 1936959X     Source Type: Journal    
DOI: 10.3174/ajnr.A2593     Document Type: Article

References (13)

1. Rutar FJ, Augustine SC, Kaminski MS, et al. Feasibility and safety of outpatient Bexxar therapy (tositumomab and iodine I 131 tositumomab) for non-Hodgkin's lymphoma based on radiation doses to family members. Clin Lymphoma 2001;2:164-72 (Pubitemid 34092722)
2. Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed lowgrade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001;19:3918-28 (Pubitemid 32912019)
3. Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine (131) I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000;96:1259-66
4. Davies AJ. A review of tositumomab and I (131) tositumomab radioimmunotherapy for the treatment of follicular lymphoma. Expert Opin Biol Ther 2005;5:577-88 (Pubitemid 40598089)
5. Kaminski MS, Tuck M, Estes J, et al. 131 I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005;352:441-49 (Pubitemid 40175970)
6. Davies AJ. Tositumomab and iodine [131I] tositumomab in the management of follicular lymphoma: an oncologist's view. Q J Nucl Med Mol Imaging 2004;48:305-16 (Pubitemid 43932940)
7. Kaminski MS, Radford JA, Gregory SA, et al. Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab. J Clin Oncol 2005;23:7985-93 (Pubitemid 46657399)
8. Davies AJ, Rohatiner AZ, Howell S, et al. Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2004;22:1469-79 (Pubitemid 41103630)
9. Kaminski M. Bexxar, iodine I 131 tositumomab, effective in long-term follow-up of non-Hodgkin's lymphoma. Cancer Biol Ther 2007;6:996-97
10. Smith S, Sweetenham JW. Iodine 131 tositumomab in the treatment of non-Hodgkin's lymphoma. Future Oncol 2007;3:255-62 (Pubitemid 47018636)
11. Dosik AD, Coleman M, Kostakoglu L, et al. Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma. Cancer 2006;106:616-22 (Pubitemid 43157625)
12. William BM, Bierman PJ. I-131 tositumomab. Expert Opin Biol Ther 2010;10:1271-78
13. Cheung MC, Maceachern JA, Haynes AE, et al. I-tositumomab in lymphoma. Curr Oncol 2009;16:32-47